[HTML][HTML] Model-informed precision dosing: State of the art and future perspectives

IK Minichmayr, E Dreesen, M Centanni, Z Wang… - Advanced drug delivery …, 2024 - Elsevier
Abstract Model-informed precision dosing (MIPD) stands as a significant development in
personalized medicine to tailor drug dosing to individual patient characteristics. MIPD moves …

Identifying the association between tacrolimus exposure and toxicity in heart and lung transplant recipients: a systematic review

HE Braithwaite, DR Darley, J Brett, RO Day… - Transplantation …, 2021 - Elsevier
Aims Tacrolimus is the cornerstone of immunosuppression management in heart and lung
transplant recipients, improving overall survival. However, tacrolimus-associated toxicities …

Investigating tacrolimus disposition in paediatric patients with a physiologically based pharmacokinetic model incorporating CYP3A4 ontogeny, mechanistic …

M Van der Veken, J Brouwers, AC Ozbey, K Umehara… - Pharmaceutics, 2023 - mdpi.com
Tacrolimus is a crucial immunosuppressant for organ transplant patients, requiring
therapeutic drug monitoring due to its variable exposure after oral intake. Physiologically …

Avoiding tacrolimus underexposure and overexposure with a dosing algorithm for renal transplant recipients: a single arm prospective intervention trial

MI Francke, LM Andrews, HL Le… - Clinical …, 2021 - Wiley Online Library
Bodyweight‐based tacrolimus dosing followed by therapeutic drug monitoring is standard
clinical care after renal transplantation. However, after transplantation, a meager 38% of …

A prospective controlled, randomized clinical trial of kidney transplant recipients developed personalized tacrolimus dosing using model-based Bayesian Prediction

N Lloberas, JM Grinyó, H Colom, A Vidal-Alabró… - Kidney International, 2023 - Elsevier
For three decades, tacrolimus (Tac) dose adjustment in clinical practice has been calculated
empirically according to the manufacturer's labeling based on a patient's body weight. Here …

Population pharmacokinetic analyses of tacrolimus in non-transplant patients: a systematic review

CB Wang, Y Zhang, MM Zhao, L Zhao - European Journal of Clinical …, 2023 - Springer
Background and objectives Tacrolimus (TAC) has been increasingly used in patients with
non-transplant settings. Because of its large between-subject variability, several population …

Interaction between tacrolimus and calcium channel blockers based on CYP3A5 genotype in Chinese renal transplant recipients

H Zong, Y Zhang, F Liu, X Zhang, Y Yang… - Frontiers in …, 2024 - frontiersin.org
Objective To investigate the effect of calcium channel blockers (CCBs) on tacrolimus blood
concentrations in renal transplant recipients with different CYP3A5 genotypes. Methods This …

Customizing tacrolimus dosing in kidney transplantation: focus on pharmacogenetics

N Lloberas, A Vidal-Alabró… - Therapeutic Drug …, 2025 - journals.lww.com
Different polymorphisms in genes encoding metabolizing enzymes and drug transporters
have been associated with tacrolimus pharmacokinetics. In particular, studies on CYP3A4 …

Model-informed precision dosing of tacrolimus: a systematic review of population pharmacokinetic models and a benchmark study of software tools

Y Hoffert, N Dia, T Vanuytsel, R Vos, D Kuypers… - Clinical …, 2024 - Springer
Abstract Background and Objective Tacrolimus is an immunosuppressant commonly
administered after solid organ transplantation. It is characterized by a narrow therapeutic …

Body composition is associated with tacrolimus pharmacokinetics in kidney transplant recipients

MI Francke, WJ Visser, D Severs… - European Journal of …, 2022 - Springer
Purpose A population pharmacokinetic (popPK) model may be used to improve tacrolimus
dosing and minimize under-and overexposure in kidney transplant recipients. It is unknown …